Recently, a large multicenter trial including 1955 patients prior to initial prostate biopsy compared performance of urinary HOXC6 and DLX1 mRNA (combined with other risk factors) with Prostate Cancer Prevention Trial Risk Calculator (PCPTRC). The gene discussed is DLX1; the disease is prostate cancer.